[go: up one dir, main page]

Oropesa-Nuñez et al., 2016 - Google Patents

Interaction of toxic and non-toxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy

Oropesa-Nuñez et al., 2016

View HTML
Document ID
6311100666536766779
Author
Oropesa-Nuñez R
Seghezza S
Dante S
Diaspro A
Cascella R
Cecchi C
Stefani M
Chiti F
Canale C
Publication year
Publication venue
Oncotarget

External Links

Snippet

Protein misfolded oligomers are considered the most toxic species amongst those formed in the process of amyloid formation and the molecular basis of their toxicity, although not completely understood, is thought to originate from the interaction with the cellular …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Similar Documents

Publication Publication Date Title
Oropesa-Nuñez et al. Interaction of toxic and non-toxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy
Burke et al. Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration
Bhatia et al. Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity
Viles Imaging amyloid‐β membrane interactions: ion‐channel pores and lipid‐bilayer permeability in Alzheimer's disease
Lee et al. Amyloid β ion channels in a membrane comprising brain total lipid extracts
Laulagnier et al. Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons
Fu et al. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan
Sugiura et al. High membrane curvature enhances binding, conformational changes, and fibrillation of amyloid-β on lipid bilayer surfaces
Bram et al. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies
Burke et al. Huntingtin disrupts lipid bilayers in a polyQ-length dependent manner
Burke et al. Amyloid-forming proteins alter the local mechanical properties of lipid membranes
Chaibva et al. Sphingomyelin and GM1 influence huntingtin binding to, disruption of, and aggregation on lipid membranes
Gao et al. Cholesterol modifies huntingtin binding to, disruption of, and aggregation on lipid membranes
Canale et al. Amyloid and membrane complexity: The toxic interplay revealed by AFM
Morris et al. Traffic of prion protein between different compartments on the neuronal surface, and the propagation of prion disease
US20100093001A1 (en) Means and methods for the production of amyloid oligomers
Henry et al. Interaction of Aβ1–42 amyloids with lipids promotes “off-pathway” oligomerization and membrane damage
Oren et al. Aβ42 double mutant inhibits Aβ42-induced plasma and mitochondrial membrane disruption in artificial membranes, isolated organs, and intact cells
Chaudhary et al. α-Synuclein oligomers stabilize pre-existing defects in supported bilayers and propagate membrane damage in a fractal-like pattern
Seghezza et al. Cholesterol drives Aβ (1–42) interaction with lipid rafts in model membranes
Matsubara et al. Size and shape of amyloid fibrils induced by ganglioside nanoclusters: role of sialyl oligosaccharide in fibril formation
Pan et al. Membrane disruption mechanism of a prion peptide (106–126) investigated by atomic force microscopy, Raman and electron paramagnetic resonance spectroscopy
Leri et al. Molecular insights into cell toxicity of a novel familial amyloidogenic variant of β2‐microglobulin
Bera et al. Comparison of synthetic neuronal model membrane mimics in amyloid aggregation at atomic resolution
Malishev et al. Interactions between BIM protein and beta-amyloid may reveal a crucial missing link between Alzheimer’s disease and neuronal cell death